RBC Capital has once again stamped an "Outperform" rating on The Cigna Group, signaling steady analyst confidence. The price ...

Guardant Health's Shield test receives FDA breakthrough status and NCCN guideline inclusion, with high accuracy shown in new ...

Cigna’s first-quarter report shows strong numbers, but Barclays warns the road ahead could get rocky. Barclays highlights ...

CVS is trading at a trailing 12-month price-to-earnings, a commonly used multiple for valuing healthcare stocks, of 9.65X, ...

Boards have increasingly benchmarked against peers as companies release more detailed pay data, per the research.

The Dow Jones surged on the stock market today. Treasury Secretary Bessent spoke out on China amid tariff progress. Alibaba cleared an entry.

The subdued stock price reaction suggests that The Cigna Group's (NYSE:CI) strong earnings didn't offer any surprises. Our analysis suggests that investors might be missing some promising details.

On Wednesday, Bernstein analysts increased their price target for Cigna Corporation (NYSE: CI) shares from $323.00 to $373.00, while maintaining a Market Perform rating.The healthcare giant, with a ...

Discover comprehensive analysis of Cigna and 1,400+ other stocks through detailed Pro Research Reports available on InvestingPro. The new price target of $373 reflects a modest reduction in policy ...

The company’s conservative guidance for the upcoming quarter is viewed as a reflection of a cautious but sustainable growth approach, supported by its low beta of 0.52 and consistent dividend payments ...

Jefferies lifts Cigna stock price target to $397, maintains buy rating ...

The stock’s performance remains strong within its 52-week range of $262.03 to $370.83, indicating positive market sentiment. Based on InvestingPro’s Fair Value analysis, Cigna appears undervalued, ...